Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …

Microsatellite unstable (MSI) colorectal cancers (CRCs) are due to DNA mismatch repair
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …

Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …

ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have recently entered into the
therapeutic scenario of metastatic breast cancer. However, only a proportion of patients …

Introduction Hepatocellular carcinoma (HCC) remains a frequently diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Recent years have …

PURPOSE: In patients with stage III colon cancer (CC) whose tumors demonstrate
microsatellite instability (MSI), the efficacy of adjuvant fluoropyrimidine (FP) with or without …

BACKGROUND Immunotherapy, especially the use of immune checkpoint inhibitors, has
revolutionized the management of several different cancer types in recent years. However …

Introduction Hepatocellular carcinoma (HCC) represents the sixth most commonly
diagnosed malignancy worldwide, accounting for millions of deaths annually. Despite …

Hepatocellular carcinoma (HCC) represents the most commonly diagnosed liver cancer
worldwide, and the overall survival of patients with unresectable disease is poor. In the last …

Immune checkpoint inhibitors (ICIs) are shown to be effective among patients with metastatic
colorectal cancer (mCRC) harboring high microsatellite instability (MSI-H) and/or mismatch …